Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Nastech off after Procter & Gamble ends deal

NSTK fell $5.37 (38%) to $8.62 on Wednesday after PG ended a

Read the full 126 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE